Holland Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Holland Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$24.1M	Sell	187,235 -44,051	-19%	-$5.3M	1.06%	42
2017 Q1	$25.3M	Sell	231,286 -47,626	-17%	-$4.19M	1.08%	44
2016 Q4	$20.5M	Buy	278,912 +58,224	+26%	+$4.74M	0.86%	49
2016 Q3	$19.2M	Sell	220,688 -19,865	-8%	-$1.88M	0.79%	49
2016 Q2	$20.7M	Sell	240,553 -117,506	-33%	-$10.2M	0.8%	50
2016 Q1	$28.5M	Buy	358,059 +101,682	+40%	+$9.2M	0.75%	48
2015 Q4	$32.3M	Sell	256,377 -8,016	-3%	-$968K	0.83%	45
2015 Q3	$27.5M	Sell	264,393 -16,810	-6%	-$2.16M	0.72%	49
2015 Q2	$34.7M	Sell	281,203 -14,099	-5%	-$1.78M	0.83%	47
2015 Q1	$34.8M	Sell	295,302 -12,333	-4%	-$1.48M	0.79%	47
2014 Q4	$36.5M	Sell	307,635 -142,439	-32%	-$16M	0.84%	44
2014 Q3	$50.5M	Sell	450,074 -320,113	-42%	-$30.5M	1.09%	39
2014 Q2	$72.9M	Sell	770,187 -518,176	-40%	-$36.3M	1.54%	31
2014 Q1	$91.1M	Sell	1,288,363 -45,602	-3%	-$3.61M	1.97%	23
2013 Q4	$99.1M	Buy	1,333,965 +8,692	+0.7%	+$605K	2.05%	18
2013 Q3	$100M	Buy	1,325,273 +450,123	+51%	+$35.8M	2.33%	13
2013 Q2	$70.1M	Buy	+875,150	New	+$64.4M	1.77%	26

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Holland Capital Management's VRTX Position: Q2 2017 in Review

Holland Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2017, selling an estimated $5.3M and leaving 187,235 shares worth $24.1M. The position accounts for 1.06% of the portfolio, ranked #42.

Holland Capital Management first reported a position in VRTX in Q2 2013 and has held it in 17 quarters since. The position peaked at $100M in Q3 2013. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Holland Capital Management held 187,235 shares of Vertex Pharmaceuticals worth $24.1M as of Q2 2017.
Holland Capital Management sold 44,051 Vertex Pharmaceuticals shares in Q2 2017, an estimated $5.3M.
Vertex Pharmaceuticals made up 1.06% of Holland Capital Management's portfolio in Q2 2017, its #42 holding.
Holland Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Holland Capital Management's Vertex Pharmaceuticals position peaked at $100M in Q3 2013.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Holland Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.